We are live on ! Find out more
PPH icon

VanEck Pharmaceutical ETF
PPH

60 hedge funds and large institutions have $177M invested in VanEck Pharmaceutical ETF in 2016 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 13 increasing their positions, 19 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

75% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 4

26% more capital invested

Capital invested by funds: $141M → $177M (+$36.4M)

11.77% more ownership

Funds ownership: 40.69% → 52.45% (+12%)

3% more funds holding

Funds holding: 58 → 60 (+2)

8% less call options, than puts

Call options by funds: $419K | Put options by funds: $454K

32% less repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 19

Holders
60
Holders Change
+2
Holders Change %
+3.45%
% of All Funds
1.6%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
13
Reduced
19
Closed
4
Calls
$419K
Puts
$454K
Net Calls
-$35K
Net Calls Change
-$33K

Top Buyers

Rank Fund Capital Flow
1
Citigroup
Citigroup
New York
+$39M
2
Goldman Sachs
Goldman Sachs
New York
+$17.1M
3
VF
Virtu Financial
New York
+$2.42M
4
Citadel Advisors
Citadel Advisors
Florida
+$2.27M
5
LCM
LVM Capital Management
Michigan
+$461K

Top Sellers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
-$6.83M
2
CI
Clal Insurance
Israel
-$3.26M
3
CS
Credit Suisse
Switzerland
-$3.03M
4
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$2.28M
5
RJFSA
Raymond James Financial Services Advisors
Florida
-$2.07M
Name Holding Trade Value Shares
Change 		Change in
Stake
Bank of New York Mellon
26
Bank of New York Mellon
New York
$287K – – –
KFC
27
Klingenstein Fields & Co
New York
$287K – – –
NAM
28
NTV Asset Management
West Virginia
$278K -$48K -800 -14%
JWM
29
Jacobus Wealth Management
Wisconsin
$274K – – –
RCG
30
Ruggie Capital Group
Florida
$272K – – –
FPCM
31
Financial Partners Capital Management
New York
$260K – – –
MFS
32
MSI Financial Services
Massachusetts
$242K -$131K -2,180 -34%
Millennium Management
33
Millennium Management
New York
$231K -$296K -4,927 -55%
Susquehanna International Group
34
Susquehanna International Group
Pennsylvania
$229K -$2.28M -38,027 -90%
FMW
35
Farr Miller & Washington
District of Columbia
$229K – – –
TSS
36
Two Sigma Securities
New York
$228K +$238K +3,970 New
Creative Planning
37
Creative Planning
Kansas
$210K – – –
SB
38
Suntrust Banks
Georgia
$204K +$210K +3,497 New
Bank of Montreal
39
Bank of Montreal
Ontario, Canada
$170K – – –
JP Morgan Chase
40
JP Morgan Chase
New York
$133K -$41.3K -688 -23%
HIIFS
41
Harel Insurance Investments & Financial Services
Israel
$78K -$24K -400 -23%
MA
42
MUFG Americas
New York
$69K -$40.8K -680 -36%
TCM
43
Tradewinds Capital Management
Washington
$69K – – –
HCM
44
Highlander Capital Management
New Jersey
$63K – – –
GT
45
Glenmede Trust
Pennsylvania
$57K – – –
NSIM
46
North Star Investment Management
Illinois
$54K +$23.4K +390 +71%
ASN
47
Advisory Services Network
Georgia
$44K +$120 +2 +0.3%
CG
48
Cutler Group
California
$38K – – –
TRCT
49
Tower Research Capital (TRC)
New York
$25K +$26.5K +442 New
EDRH
50
Edmond de Rothschild Holding
Switzerland
$23K +$12K +200 +100%
1
2
3

PPH Hedge Fund Activity: Q3 2016 in Review

60 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in VanEck Pharmaceutical ETF (PPH) for Q3 2016, worth a combined $177M — up 26% from $141M a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new PPH positions and 4 closed out — a net gain of 3 holders — while 13 added to existing stakes and 19 trimmed.

The largest buyer was Citigroup, adding an estimated $39M. The largest seller was Morgan Stanley, cutting an estimated $6.83M.

  • 60 institutional investors held VanEck Pharmaceutical ETF (PPH) as of Q3 2016, up from 58 in Q2 2016.
  • Funds reported $177M of VanEck Pharmaceutical ETF stock for Q3 2016, up 26% quarter-over-quarter.
  • 7 funds opened new VanEck Pharmaceutical ETF positions in Q3 2016 and 4 closed out, a net change of +3 holders.
  • The largest VanEck Pharmaceutical ETF buyer in Q3 2016 was Citigroup, an estimated $39M added.
  • The largest VanEck Pharmaceutical ETF seller in Q3 2016 was Morgan Stanley, an estimated $6.83M sold.

Based on aggregated 13F filings for Q3 2016.